GH Research PLC (NASDAQ:GHRS - Get Free Report) dropped 7.6% on Thursday . The company traded as low as $14.25 and last traded at $13.86. Approximately 198,904 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 775,802 shares. The stock had previously closed at $15.00.
Wall Street Analysts Forecast Growth
GHRS has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group lowered their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th.
Get Our Latest Report on GH Research
GH Research Stock Up 1.5 %
The stock has a market capitalization of $733.10 million, a PE ratio of -17.84 and a beta of 0.93. The stock's 50-day moving average is $9.03 and its 200 day moving average is $9.01.
Institutional Trading of GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. lifted its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
